display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic/advanced hepatocellular cancer (mHCC)
mHCC - (neo)adjuvant (NA)
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab plus bevacizumab IMbrave050
sintilimab based treatment
sintilimab Wang
Immune checkpoint association
nivolumab plus ipilimumab NCI-2018-01106

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons